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Abstract 
Background: Cerebrospinal fluid (CSF) biomarkers of the beta-amyloid and microtubule 
associated protein tau metabolism have proven the capacity to improve classification of subjects 
developing Alzheimer disease (AD).  The blood plasma proteome was characterized to further 
elaborate upon the mechanisms involved and identify proteins that may improve classification of 
older adults developing an AD dementia.     
Objective: Identify and describe plasma protein expressions that best classify subjects with CSF-
defined presence of AD pathology and cerebral amyloidosis. 
Methods: We performed a cross-sectional analysis of samples collected from community-
dwelling elderly with (n = 72) or without (n = 48) cognitive impairment. CSF Aβ1-42, tau and 
phosphorylated tau (P-tau181) were measured using ELISA and mass spectrometry quantified the 
plasma proteomes. Presence of AD pathology was defined as CSF P-tau181/Aβ1-42 > 0.0779 
and presence of amyloidosis was defined as CSF Aβ1-42 < 724 pg/mL.   
Results: Two hundred and forty-eight plasma proteins were quantified. Plasma proteins did not 
improve classification of the AD CSF biomarker profile in the whole sample. When the analysis 
was separately performed in the cognitively impaired individuals, the diagnosis accuracy of AD 
CSF profile was 88.9% with 19 plasma proteins included.  Within the full cohort, there were 16 
plasma proteins that improved diagnostic accuracy of cerebral amyloidosis to 92.4%. 
Conclusion: Plasma proteins improved classification accuracy of AD pathology in cognitively-
impaired older adults and appeared representative of amyloid pathology. If confirmed, those 
candidates could serve as valuable blood biomarkers of the preclinical stages of AD or risk of 
developing AD. 
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Introduction 
The prevalence of dementia is expanding rapidly and Alzheimer disease (AD) represents its most 
common form (60-80% of cases) [1]. AD is characterized by a long prodromal phase that 
precedes the apparition of the symptoms, with accumulation of amyloid-beta (Aβ) plaques and 
aggregation of hyperphosphorylated tau as neurofibrillary tangles in the brain [2]. This long 
prodromal stage poses several challenges to define accurate and early enough AD diagnostics for 
tailoring and monitoring intervention strategies [3, 4].  
The quest for blood-based biomarkers for neurological disorders is pursued by many researchers 
due to the easily available, minimally invasive and repeatable sampling of blood. Research in the 
AD field has generated several candidates but well-accepted molecular biomarkers are still 
measured in cerebrospinal fluid (CSF) [5]. In particular, protein biomarkers in plasma or serum 
have been reported to differentiate AD or mild-cognitive impairment (MCI) from non-demented 
controls [6]. Unfortunately, most of the discovery findings have not been replicated, preventing 
the translation into an AD diagnostic test of clinical utility. This lack of replication might be due 
to several causes, either inherent to the technology or the biology, but also characteristic of the 
difficulty of designing proper case-control studies for a disease with such a long prodromal stage. 
To address such a challenge, endophenotype approaches have been followed [7], where 
pathology profiles of AD are used as proxy measures. According to the temporal model of AD 
biomarker alterations by Jack et al. [8], decreased concentration of CSF Aβ1-42 constitutes the 
earliest detectable event and may precede the onset of dementia by more than 20 years [9]. It is 
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followed by increased concentration of CSF tau, brain atrophy, and impairment in brain glucose 
metabolism. Blood-based biomarkers that can reflect CSF Aβ1-42 and tau concentrations are 
therefore of particular interest. As amyloid pathology develops at very early disease stages, CSF 
Aβ1-42 may be considered as an early pre-dementia and pre-clinical stage biomarker of AD [7]. 
In this study, we applied a state-of-the-art mass spectrometry (MS)-based proteomics workflow 
[10] to measure plasma proteome profiles of 120 older community-dwelling adults. While many 
MS-based proteomic biomarker discovery studies have been performed in cohorts of very limited 
size due to technical limitations, our highly automated methodology can analyze hundreds of 
samples and provide sufficient statistical power to deliver robust discovery findings [11]. Using 
an endophenotype approach to define preclinical AD and cerebral amyloidosis based on CSF 
measurements of phosphorylated tau 181 (P-tau181)/Aβ1-42 ratio and Aβ1-42 concentration 
respectively, we aimed at identifying plasma-based protein biomarker candidates that could 
detect positive CSF profiles of AD pathology and amyloidosis to provide mechanistic insights 
and potential diagnostics sensitive to the preclinical stages of AD.  
 
 
Materials and methods 
Study population. One hundred and twenty community dwelling participants were included in 
this study, of whom 48 were cognitively healthy volunteers and 72 had mild cognitive 
impairment (mild cognitive impairment (MCI), n = 63, or mild dementia of AD type, n = 9) [12]. 
Diagnosis of mild cognitive MCI or dementia was based on neuropsychological and clinical 
evaluation, and made by a consensus conference of psychiatrists and/or neurologists, and 
neuropsychologists prior to the inclusion into the study. The participants with cognitive 
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impairment were recruited among outpatients who were referred to the Memory Clinics, 
Departments of Psychiatry, and Department of Clinical Neurosciences, University Hospitals of 
Lausanne (Switzerland). They had no major psychiatric disorders, nor substance abuse or severe 
or unstable physical illness that may contribute to cognitive impairment, had a clinical dementia 
rating (CDR) [13] score > 0, and met the clinical diagnostic criteria for MCI [14] or AD mild 
dementia according to the recommendations from the National Institute on Aging and 
Alzheimer’s Association [15]. In the current study, 9 subjects met criteria for probable AD 
dementia. As there is a clinical continuum between MCI and mild dementia, and the participants 
with cognitive impairment were patients from memory clinics recruited in the same way 
irrespective of MCI or mild dementia classification, these subjects were collapsed and labeled as 
cognitively impaired with CDR > 0. The control subjects were recruited through journal 
announcements or word of mouth and had no history, symptoms, or signs of relevant psychiatric 
or neurologic disease and no cognitive impairment (CDR = 0). All participants underwent a 
comprehensive clinical and neuropsychological evaluation, structural brain imaging, and venous 
and lumbar punctures [12]. Magnetic resonance imaging and computerized tomography scans 
were used to exclude cerebral pathologies possibly interfering with the cognitive performance. 
Neuropsychological tests were used to assess cognitive performance in the domains of memory 
[16], language, and visuo-constructive functions. The mini mental state examination [17] was 
used to assess participants’ global cognitive performance. Depression and anxiety were assessed 
using the hospital anxiety and depression scale [18]. The psychosocial and functional assessments 
included the activities of daily living (ADL) and instrumental ADL, the neuropsychiatric 
inventory questionnaire and informant questionnaire on cognitive decline in the elderly [19], and 
were completed by the family members of the participants. All tests and scales are validated and 
widely used in the field. 
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The institutional ethical committee from the University Hospitals of Lausanne approved the 
clinical protocol (No. 171/2013) and all participants or their legally-authorized representatives 
signed written informed consent. 
CSF and plasma sample collection. Venous and lumbar punctures were performed between 
8:30-9:30 am after overnight fasting. For lumbar puncture, a standardized technique with a 22 
gauge “atraumatic” spinal needle and a sitting or lying position was applied [20]. A volume of 
10-12 mL of CSF was collected in polypropylene tubes. Routine cell count and protein 
quantification were performed. Remaining CSF was frozen in aliquots (500 μL) no later than 1 h 
after collection and stored at -80 °C without thawing until assay. Blood was drawn into EDTA 
K3 containing S-Monovette (Sarstedt, Nümbrecht, Germany). After maximum 20-30 min on ice, 
the tubes were centrifuged at 3000 rpm for 12 min at 6 °C. Volumes of 350 μL plasma samples 
were aliquoted 2-5 min after centrifugation into polypropylene tubes, frozen no later than 1 h 
after collection, and stored at -80 °C. Plasma aliquots were not thawed before the proteomic 
experiment.  
CSF Aβ1-42, tau, P-tau181 and APOE ε4 genotyping. The measurements were performed using 
commercially available ELISA kits and Taqman assays as described in Supplementary Methods 
of the Supplementary Material. CSF and blood samples were collected as previously described 
[12]. 
Primary outcome measures - CSF profile of AD pathology (AD CSF profile). A pathological 
AD CSF profile was defined as CSF P-tau181/Aβ1-42 ratio > 0.0779 (i.e., “high” ratio for 
positive CSF profiles of AD pathology), based on clinical study site data [21] and in line with 
previous works (i.e., 0.08) [22]. The cutoff optimized the Youden index [23] of the receiver 
operating characteristic (ROC) curve for the prediction of CDR categories (CDR = 0 versus CDR 
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> 0) (Supplementary Figure S1A) as previously reported [12], where the cutoff for CSF P-
tau181/Aβ1-42 ratio was further confirmed to be a highly significant predictor of cognitive 
decline.  
Primary outcome measures - CSF profile of amyloid pathology (amyloid pathology CSF 
profile). Subjects were classified into two groups on the basis of their CSF Aβ1-42 
concentrations as “low” when [Aβ1-42] < 724 pg/mL or “high” when [Aβ1-42] ≥ 724 pg/mL, 
considered as positive and negative CSF profiles of amyloid pathology, respectively. The cutoff 
optimized the Youden index [23] of the ROC curve for the prediction of CDR categories (CDR = 
0 versus CDR > 0) (Supplementary Figure S1B).  
Proteomic analysis. Plasma samples were measured using a shotgun proteomic workflow based 
on liquid chromatography (LC) tandem MS (MS/MS), as previously reported [10] and described 
in details in the Supplementary Methods of the Supplementary Material. Relative 
quantification of proteins between the samples was obtained using isobaric tagging with the 
tandem mass tag (TMT) technology [24]. 
Biomarker quality control. In total, 422 human proteins were identified in the plasma samples. 
Proteins with greater than 5% missingness were excluded, leaving 248 quality-controlled proteins 
(Supplementary Table TS1). Remaining missing data (5% or less per protein) were imputed by 
randomly drawing a value between the observed range of biomarker values. Log2 of the protein 
ratio fold changes were scaled to mean 0 and standard deviation of 1 prior to statistical analyses. 
Two samples were removed because of aberrant values of the internal standard (Supplementary 
Methods of the Supplementary Material), leaving plasma proteomic data available for 118 
subjects. 
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A strong clustering effect was observed in the heatmap of the plasma proteome profiles 
(Supplementary Figure S2). This effect involved 37 proteins with clear differential abundance 
pattern. It was not associated with any of the available clinical covariates but with other 
molecular measures in plasma such as amino-acids and microRNAs (data not shown). Those 37 
proteins were carried further for the statistical analysis but are marked with # when mentioned in 
the text.  
Statistical analyses. Calculation and statistics were performed with R version 3.3.2 
(http://www.r-project.org/). Least absolute shrinkage and selection operator (LASSO) logistic 
regression [25] selected biomarkers that best predict CSF profiles of AD and amyloid pathology. 
A reference model was initially generated, testing variables that are likely to be available to 
clinicians and known risk factors for AD to provide a benchmark for comparison with the models 
that included plasma proteins. These inputs included age, gender, years of education, and 
presence of the APOE ε4 allele. In addition of all variables used to make the reference models, 
protein measurements and CSF albumin index were then included in building so-called best 
models. A 10-fold cross-validation process was performed for each LASSO analysis using the 
glmnet package [26], which allows estimating the confidence interval of the misclassification 
error for each value of the regularization parameter λ. The LASSO analyses were repeated 100 
times (1000 times for the reference models). The models that minimized the upper limit of the 
cross-validated misclassification error confidence interval across the 100 runs with less than 20 
features were selected. Their performance was assessed by ROC area under the curve (AUC) 
estimation using a bootstrap approach with 1000 iterations [27]. Results were compared visually 
and formally tested for significance against the reference model using ROC AUC [28] and 
accuracy using a McNemar test. 
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The group differences for the proteins selected in the best models were graphically illustrated in 
boxplots and assessed using t-test statistics, adjusted for multiple testing by the total number of 
proteins tested with Bonferroni correction. 
 
 
Results  
Demographic and clinical characteristics of the study population. Demographics and clinical 
characteristics of the patient cohort are detailed in Table 1. The cognitively impaired subjects 
with MCI and mild dementia were considered together as one group (CDR > 0) (see the 
Materials and methods section); they were older and less educated, with higher prevalence of 
APOE ε4 genotype compared with the cognitively intact group (CDR = 0). In cognitive 
impairment, CSF Aβ1-42 was lower while CSF tau, CSF P-tau181, CSF P-tau181/Aβ1-42 and 
CSF albumin index were all higher. 
The classification analysis of the CSF P-tau181/Aβ1-42 ratios aimed first at separating 42 
patients with high-expression CSF profile (P-tau181/Aβ1-42  > 0.0779) from 78 low-expression 
profile subjects in the complete analysis set (Table 1), irrespectively of the clinical diagnosis. 
Then the analysis was performed on the subset of cognitively impaired patients. In this 
subpopulation, 41 and 31subjects had high and low-expression of AD CSF biomarker profile, 
respectively.  
The classification analysis of the CSF Aβ1-42 concentration categories aimed at separating 47 
patients with low-expression CSF profile ([Aβ1-42] < 724 pg/mL) from 73 high-expression 
profile subjects (Table 1), irrespectively of the clinical diagnosis. 
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Reference benchmark for the prediction of AD CSF profile. In the whole sample, the selected 
reference model for classification of CSF P-tau181/Aβ1-42 included age and presence of the 
APOE ε4 allele. Its prediction accuracy was 78.3% (as compared to the accuracy of a majority 
class prediction [29] of 64.4%) and its AUC under the ROC curve was 0.83 (95% confidence 
interval [0.74-0.90]) (Figure 1A and Table 2).  
In the subset of cognitively impaired subjects, the reference model to classify AD CSF biomarker 
profile included age, gender, years of education, and presence of APOE ε4 allele, with a 
prediction accuracy of 77.8% (majority class prediction of 56.9%) and an AUC under the ROC 
curve of 0.83 [0.73-0.91] (Figure 1B and Table 2).  
Plasma proteins and prediction of AD CSF profile. Protein biomarkers were not able to improve 
the prediction of AD CSF biomarker profile with respect to the reference model (Figure 1A, 
Table 2, and Supplementary Figure S3A). The best model accuracy was 80.5% (McNemar p-
value of 0.1814 when compared with reference model) and AUC under the ROC curve was 0.88 
[0.81-0.93] (p = 0.1414 versus the reference model as shown in Figure 1A). It included four 
proteins (Supplementary Table TS1) in addition of age and presence of APOE ε4 allele. Despite 
not leading to a significant improvement, all four proteins displayed significant group comparison 
differences, i.e., insulin-like growth factor-binding protein 2 (IBP2) (p = 9.3 × 10−5), complement 
component C7 (CO7) (p = 4.9 × 10−4), noelin (NOE1) (p = 1.3 × 10−3), and apolipoprotein E 
(APOE) (p = 0.04) (Supplementary Figure S4). 
When considering separately the cognitively impaired subjects, inclusion of protein biomarkers 
improved significantly diagnostic accuracy to 88.9% (McNemar p-value of 0.0990) with an AUC 
under the ROC curve of 0.96 [0.90-0.99] (p = 0.0038 as shown in Figure 1B; see also Table 2 
and Supplementary Figure S3B). In total, 19 proteins (Supplementary Table TS1) were 
included in this best model in addition of presence of APOE ε4 allele. Among those proteins, 
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seven displayed significant difference between the groups: IBP2 (p = 3.0 × 10−3), CO7 (p = 0.01), 
apolipoprotein M (APOM) (p = 0.02), selenoprotein P (SEPP1) (p = 0.02), NOE1 (p = 0.04), 
angiotensinogen (ANGT) (p = 0.04), and pregnancy zone protein (PZP) (p = 0.05) 
(Supplementary Figure S5). 
Reference benchmark for the prediction of amyloid pathology CSF profile. The reference 
model for classification of CSF Aβ1-42 was composed of age, gender, years of education, and 
presence of the APOE ε4 allele. Its prediction accuracy was 80.0% (as compared to the accuracy 
of a majority class prediction of 60.2%) and its AUC under the ROC curve was 0.86 [0.78-0.92] 
(Figure 2A and Table 2). 
Plasma proteins and prediction of amyloid pathology CSF profile. Plasma protein biomarkers 
were able to predict CSF Aβ1-42 categories with high accuracy, i.e., diagnostic accuracy of 
92.4% (McNemar p-value of 0.0022) and AUC under the ROC curve of 0.96 [0.93-0.99] (p = 
0.0040 as shown in Figure 2A; see also Table 2, and Supplementary Figure S6). In total 16 
proteins (Supplementary Table TS1) were selected in this best model in addition of age and 
presence of APOE ε4 allele. As shown in Figure 2B, significant group differences were observed 
for IBP2 (p = 2.4 × 10−3), uncharacterized protein KIAA0753 (K0753) (p = 3.2 × 10−3), CO7 (p = 
9.5 × 10−3), C-reactive protein (CRP) (p = 0.01), ovochymase-1 (OVCH1) (p = 0.01), 
ceruloplasmin (CERU) (p = 0.02), and sex hormone-binding globulin (SHBG) (p = 0.02). 
Protein panel overlaps and annotations. In total, 32 plasma proteins were included in all three 
best models presented above for classification of CSF-defined AD and amyloid pathology. The 
overlap of the molecular protein panels for classification of AD CSF profile in the whole sample 
and the subset with cognitive impairment is illustrated with the Venn Diagram of Figure 3A, 
showing IBP2, CO7, and NOE1 proteins as commonly selected features. The protein overlap 
between biomarker panels improving the classification of AD and brain amyloidosis CSF profiles 
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appears on Figure 3B. Again, IBP2 and CO7 were present in both classification models. Plasma 
IBP2 and CO7 presented higher abundance in AD and amyloid pathology CSF profiles 
(Supplementary Figure S4 and Figure 1B, respectively). 
Based on the tissue-based map of the human proteome [30], only NOE1 was found to be reported 
as enriched in the cerebral cortex among the 32 proteins reported in this study. We measured 
increased levels of plasma NOE1 in individuals with AD CSF biomarker profile 
(Supplementary Figures S4 and S5). 
 
 
Discussion 
In the present study, plasma proteome profiles of 120 elderly subjects were measured with MS-
based proteomics using a highly automated shotgun workflow [31]. We evaluated if proteins in 
the peripheral circulation do accurately reflect the presence of cerebral AD pathology or cerebral 
amyloidosis as measured using well-established CSF biomarkers, and developed diagnostic 
classification models, so-called best models, to outperform benchmark reference models 
including variables likely available to clinicians and known risk factors for AD. We found 2 
panels of plasma proteins improving the diagnostic accuracy of CSF-defined AD pathology and 
amyloidosis. Age and presence of APOE ε4 allele were variables relevant to most of the 
diagnostic classification models. 
In our study, plasma proteins were useful to diagnose AD CSF profile defined as higher CSF P-
tau181/Aβ1-42 ratios (i.e., > 0.0779) only in the subset of cognitively impaired subjects. This 
restricted finding is likely due to the low number of subjects with an AD CSF profile in the group 
of subjects with normal cognition and do not exclude AD specific plasma protein alterations in 
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the asymptomatic disease stages. As CSF Aβ1-42 is considered as one of the earliest biomarkers 
of the preclinical development of cerebral AD pathology, we further investigated if plasma 
proteins could be used to classify CSF Aβ1-42 categories for early stage identification of 
susceptibility for AD. In our study, 16 proteins were selected for diagnostic classification of 
amyloid pathology. IBP2, K0753, CO7, CRP, OVCH1, CERU, and SHBG were significantly 
different between amyloidosis and non-amyloidosis representative CSF profiles.  
Plasma and serum protein panels have been proposed as biomarkers of AD pathology by several 
groups. Most significant findings have been previously [6, 7, 18] and recently [32] reviewed. Ray 
et al. reported an 18-protein panel to classify AD versus control subjects with a diagnostic 
accuracy of 90% [20]. Serum protein-based biomarkers were combined with clinical information 
(i.e., age, gender, education, and APOE status) to classify AD from controls with 94% sensitivity 
and 84% specificity while 84% sensitivity and 78% specificity were obtained using clinical 
variables alone [16]. Another example is the study by Doecke et al., reporting an 18-biomarker 
signature panel on top of age, gender and APOE ε4 genotype for the diagnosis of AD with 
sensitivity and specificity of 85% with respect to the 77% achieved with only the demographic 
variables. A panel of 10 proteins predicting progression to AD with 87% accuracy was described 
by Hye et al. [19]. In our study, diagnostic accuracy improvement from 77.8% to 88.9% (+ 
14.3%) following the inclusion of plasma protein biomarkers for the classification of AD CSF 
profile in cognitive impairment appears therefore pertinent. This accuracy improvement may be 
particularly helpful in memory clinic patients with cognitive impairment to identify those at high 
risk of having cerebral AD pathology. As blood-based diagnostic methods are non-invasive and 
easily available, they may be largely used to select patients for additional investigation with more 
invasive and/or expensive tools such as diagnostic lumbar puncture and positron emission 
tomography (PET). In addition, identifying subjects likely to have cerebral amyloid pathology 
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may be particularly important for the recruitment in prevention trials as well as for disease-
modifying therapeutic interventions targeting amyloid and starting at preclinical or very early 
clinical disease stages. In this view, the diagnostic accuracy improvement for the classification of 
amyloid pathology CSF profile from 80.0% to 92.4% (+ 15.5%) using plasma proteins offers 
interesting perspectives.   
Taken together, our results highlighted the strong contribution of three plasma proteins (i.e., 
IBP2, CO7, and NOE1) for better classification of CSF pathological profiles (Figure 3). In the 
brain, IBP2 is produced by astroglia and choroid plexus epithelial cells. , It is in the brain the 
most abundant of the six insulin-like growth factor-binding proteins, whose role is to regulate the 
availability and activity of insulin-like growth factors [33]. In previous works, IBP2 
concentration in the CSF was found to be 20% of that in the circulation [34] but both levels were 
increased in AD [35]. In line with our results, IBP2 was part of a blood-based signature to 
determine AD [36] and increased circulating plasma levels were associated with brain atrophy 
[37]. Plasma IBP2 has also been shown to be related to neurodegeneration, particularly among 
amyloid negative individuals, suggesting its role in non-AD neurotrophic signaling pathway [38]. 
In our study, IBP2 contributed to classify both positive CSF profiles of AD pathology and 
amyloidosis. Complement proteins are present in amyloid plaques and cerebral vascular amyloid 
in Alzheimer brains; they are observed at the earliest stages of amyloid deposition and their 
activation corresponds with AD clinical expression [39]. Therefore, the complement system may 
be an attractive target for therapeutic intervention [40, 41]. We reported plasma CO7, one of the 
five complement proteins of the membrane attack complex which participate to the late events of 
complement activation, to be elevated in the pathology status reflected by both abnormal CSF P-
tau181/Aβ1-42 and Aβ1-42. To the best of our knowledge, our findings on plasma NOE1 are 
novel.  NOE1 is a secreted glycoprotein expressed in neurogenic tissues during development, and 
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has an important role in regulating the production of neural crest cells [42]. As a brain-specific 
protein, NOE1 significant up-regulation in the plasma of subjects with positive CSF biomarker 
profile of AD might offer compelling diagnostic perspectives. 
Several proteins included in our putative classification models have previously been reported. 
The ε4 allele of APOE is a well-known and major genetic risk factor for AD. In addition, 
decreased plasma APOE protein levels have been shown in AD [36, 43], in accordance to our 
results. Furthermore, low plasma APOE has been found to be associated with increased risk of 
AD and dementia [44]. On the contrary, using a proteomic approach, plasma APOE 
concentration was found indicative of brain amyloid burden and a positive correlation was 
evidenced [45]. An additional apolipoprotein reported in our study is APOM which is mainly 
associated with high-density lipoprotein in plasma [46]. APOM gene was excluded as genetic 
determinant of AD [47]. But recently, APOM in CSF was found decreased in AD cases [48]. We 
reported herein increased plasma levels of APOM in subjects with AD CSF profile.  
SEPP1 has also been previously associated with Alzheimer pathology [49], underlining the 
implication of selenium and its antioxidant properties; increased levels of SEPP1, as seen here in 
AD, might be a response to oxidative stress. SEPP1 protects neuronal cells from Aβ-induced 
toxicity, suggesting a neuroprotective role of SEPP1 in preventing neurodegenerative disorders 
[50]. There are contradictory findings about CERU level changes in the blood of AD patients. No 
difference was observed when comparing its concentration in plasma or serum of AD patients to 
that of controls [51, 52]. In the plasma of patients with aberrant CSF levels of Aβ1-42, tau and its 
phosphorylated form, CERU was found to be decreased compared with AD patients with normal 
levels of these biomarkers in the CSF [53]. But serum copper and CERU levels were found 
significantly higher in AD than control group [54]. In our study, we detected using shotgun 
16 
 
proteomics higher plasma CERU levels in individuals with the pathological CSF Aβ1-42 profile 
when compared to those of controls.  
An activation of inflammatory pathways is observed in AD [55]. CRP is generally released by the 
body in response to acute injury, infection, or other inflammatory stimuli.  Nonetheless, reduced 
levels of plasma and serum CRP have been observed in AD [56-59], in agreement with results on 
the present cohort previously obtained using immunoassays [12]. Herein, we additionally 
highlighted that decreased plasma level of CRP agreed with amyloid pathology CSF profile. 
PZP (a close homolog of the antiprotease alpha-2-macroglobulin and one of the major pregnancy-
associated plasma proteins) and SHBG (a glycoprotein that binds androgen and estrogen 
hormones) are known to be present at different levels in females when compared to males [11]. 
PZP was found elevated in the serum of women in presymptomatic AD compared with controls 
[60]. Our results showed somehow the opposite, with decreased plasma levels in AD CSF profile. 
Muller et al. have observed that in both men and women higher levels of SHBG were associated 
with an increased risk for AD and overall dementia [61]. Patients with AD had higher plasma 
levels of SHBG [62]. Furthermore, we detected with proteomics an increase of plasma SHBG in 
individuals with amyloid pathology CSF profile. 
ANGT is a component of the renin-angiotensin system, a hormone system that regulates blood 
pressure and fluid balance. Up-regulation of the renin-angiotensin system in AD brains was 
reported and our observation of increased ANGT in the plasma of patients with AD CSF profile 
appeared therefore consistent [63]. To our knowledge, neither K0753 protein, which was recently 
reviewed as protein moonraker (MOONR), nor OVCH1, have been linked before to AD or 
neurodegeneration. 
In conclusion, our proteomic results suggest that several panels of plasma proteins are relevant to 
CSF-defined AD and amyloid pathology. The plasma proteome profiles have been obtained on 
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120 individuals using MS to guarantee more robust findings at the discovery phase than usually 
performed with such MS-based proteomic approaches. The cohort size remains however limited. 
Another limitation lies in the two different methods for recruitment of cognitively impaired 
subject and healthy controls that might induce cohort effect. But, the identified plasma proteins 
may serve to improve differential diagnosis in cognitively impaired older adults and to facilitate 
identification of subjects at risk of developing AD that could benefit from prevention strategies or 
clinical trials focusing on amyloid pathology. As a blood test would be less invasive and 
expensive than lumbar puncture and PET scans, the results are therefore encouraging but 
replication in an independent cohort will be needed as well as the results confirmed in relation to 
longitudinal change before further translation to clinical use. Our findings may reveal valuable in 
the quest for a blood test for the diagnosis of AD pathology at early disease stages.   
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ROC = Receiver operating characteristic 
SEPP1 = Selenoprotein P 
SHBG = Sex hormone-binding globulin 
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FIGURE CAPTIONS 
Figure 1. ROC curves of the models including plasma proteins for classification of non-AD 
versus AD CSF biomarker profiles (i.e., P-tau181/Aβ1-42 ≤ 0.0779 and P-tau181/Aβ1-42 > 
0.0779 respectively) in all subjects (A) and in subjects with cognitive impairment (B). In the 
whole cohort, the best model for AD CSF profile classification contains APOE, CO7, IBP2, and 
NOE1 in addition of age and presence of APOE ε4 allele; the reference model to outperform is 
composed of age and presence of APOE ε4 allele. In subjects with cognitive impairment, the best 
model for AD CSF profile classification contains ANGT, APOC2, APOM, CAH2 #, CC180, 
CO7, CO8G, FIBB, HBA, HXA3, IBP2, ICAM2, K0753, NOE1, OVCH1, PZP, SAMP, SEPP1, 
and TSP1# in addition of presence of APOE ε4 allele; the reference model to outperform is 
composed of age, gender, years of education, and presence of APOE ε4 allele. The opacity of the 
curves is proportional to the accuracy of the models. The diamonds indicate the selected most 
accurate models. The p-values on the graphs indicate the significance of the differences of AUC. 
Figure 2. ROC curves of the model including plasma proteins predictive of CSF Aβ1-42 levels 
(A). The best model is composed of CADH5, CERU, CO4B, CO7, CRP, FA12, FHR1, GNPTG, 
HGFL, IBP2, IPSP, K0753, KPYM #, OVCH1, RET4, and SHBG in addition of age and presence 
of APOE ε4 allele; the reference model contains age, gender, years of education, and presence of 
APOE ε4 allele. The opacity of the curves is proportional to the accuracy of the models. The 
diamonds indicate the selected most accurate models. The p-value on the graphs indicates the 
significance of the differences of AUC. Box-plots of plasma proteins according to CSF Aβ1-42 
levels, i.e., “low” when [Aβ1-42] < 724 pg/ml and “high” when Aβ1-42] ≥ 724 pg/ml for positive 
and negative CSF profiles of amyloid pathology, respectively (B). Relative protein fold change 
ratios were used. Level of significant is indicated as p-value after Bonferroni correction. 
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Figure 3. Comparison of protein panels determined with LASSO for the classification of AD 
CSF biomarker profile in the whole sample and subset with cognitive impairment (A). 
Comparison of protein panels determined with LASSO for the classification of AD pathology and 
amyloidosis CSF-defined profiles (B).  
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Table 1. Demographics and clinical characteristics. 
 
 
P-
tau181/
Aβ1-42 
≤ 0.0779 
(n = 78) 
P-
tau181/
Aβ1-42 
> 0.0779
(n = 42)
[Aβ1-42] 
≥ 724 
pg/mL 
(n = 73) 
[Aβ1-42]
< 724 
pg/mL 
(n = 47)
CDR = 0 
(n = 48) 
CDR > 0
(n = 72)
Age (years), mean 
(SD) 
68.4 
(8.3) 
74.1 
(5.6)* 
68.1 
(8.2) 
73.9 
(6.1)* 
66.0 
(7.4) 
73.3 
(6.9)* 
Gender, No. (%) of 
Males 
25 
(32.05%) 
18 
(42.86%)
26 
(35.62%)
17 
(36.17%)
17 
(35.42%) 
26 
(36.11%)
Education years, 
mean (SD) 
12.5 
(2.7) 
12.1 
(2.4) 
12.6 
(2.7) 
12.0 
(2.5) 
13.2 
(2.3) 
11.8 
(2.7)* 
CDR, score (% of 
subjects) 
0 
(60.2%) 
or 0.5 
(37.2%) 
or 1 
(2.6%) 
0  
(2.4%) 
or 0.5 
(80.9%) 
or 1 
(16.7%)
0 
(57.6%) 
or 0.5 
(39.7%) 
or 1 
(2.7%) 
0 
(12.8%) 
or 0.5 
(72.3%) 
or 1 
(14.9%)
0 (100%) 
0.5 
(87.5%) 
or 1 
(12.5%)
MMSE scale, mean 
(SD) 
27.8 
(2.3) 
25.2 
(3.7)* 
27.8 
(2.2) 
25.6 
(3.8)* 
28.5 
(1.4) 
25.9 
(3.5)* 
APOE ε4 carriers, No. 
(%) 
13 
(16.67%) 
24 
(57.14%)
* 
10 
(13.70%)
27 
(57.45%)
* 
11 
(22.92%) 
26 
(36.11%)
* 
CSF Aβ1-42 (pg/mL), 
mean (SD) 
979.9 
(196.4) 
601.2 
(190.0)*
1026.1 
(160.1) 
569.9 
(111.1)*
957.4 
(194.0) 
774.0 
(281.5)*
CSF tau (pg/mL) , 
mean (SD) 
235.1 
(104.2) 
624.2 
(322.4)*
268.2 
(155.6) 
531.4 
(346.1)*
221.5 
(82.9) 
471.1 
(316.6)*
CSF P-tau181 
(pg/mL), mean (SD) 
46.7 
(13.4) 
90.3 
(44.8)* 
51.3 
(18.8) 
78.6 
(46.9)* 
45.9 
(13.3) 
72.7 
(40.9)* 
P-tau181/Aβ1-42, 
mean (SD) 
0.05 
(0.01) 
0.16 
(0.10)* 
0.05 
(0.02) 
0.15 
(0.11)* 
0.049 
(0.015) 
0.114 
(0.097)*
AD CSF profile, No. 
(%) of subjects 
0 (0.0%) 42 
(100.0%)
* 
4 
(5.48%) 
38 
(80.85%)
* 
1 
(2.08%) 
41
(56.94%)
*
Amyloid pathology 
CSF profile, No. (%) 
of subjects 
9 
(11.54%) 
38 
(90.48%)
* 
0 (0.0%) 47 
(100.0%)
* 
6 
(12.50%) 
41 
(56.94%)
* 
CSF albumin index, 
mean (SD) 
5.9 (2.4) 6.4 (2.3) 5.9 (2.5) 6.4 (2.2) 5.3 (1.9) 6.6 (2.5)* 
*statistically different (p ≤ 0.05) from P-tau181/Aβ1-42 ≤ 0.0779, [Aβ1-42] ≥ 724 pg/mL, and 
CDR = 0, respectively, using t-tests for continuous variables and binomial proportion tests for 
categorical variables. CSF albumin index = [CSF albumin] / [serum albumin] × 100; MMSE = 
Mini Mental State Examination 
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Table 2. Performance of classification models. 
 
 
Reference 
models Best models 
AD CSF profile 
Accuracy 78.3% 80.5% 
Sensitivity 50.0% 61.9% 
Specificity 93.6% 90.8% 
AUC 0.83 [0.74-0.90]) 0.88 [0.81-0.93] 
AD CSF profile in cognitive impairment 
Accuracy 77.8% 88.9% 
Sensitivity 82.9% 85.4% 
Specificity 71.0% 93.6% 
AUC 0.83 [0.73-0.91] 0.96 [0.90-0.99]* 
Amyloid pathology CSF profile 
Accuracy 80.0% 92.4%* 
Sensitivity 82.2% 93.0% 
Specificity 76.6% 91.5% 
AUC 0.86 [0.78-0.92] 0.96 [0.93-0.99]* 
*statistically different (p ≤ 0.05) from reference model using a McNemar test (accuracy) or a 
bootstrap test (AUC). Sensitivity and specificity are given for the most accurate models. For 
AUC, 95% confidence intervals are given.   
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Figure 1. 
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Figure 2. 
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Figure 3. 
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SUPPLEMENTARY TABLE 
Table TS1. Quality-controlled plasma proteins measured with MS. The proteins indicated in bold are part of at least one of the best 
models that include plasma protein measurements. 
Entry  Entry name  Protein name  n 
Number 
of 
missing 
values 
Mean  SD  Median  AD CSF profile 
AD CSF 
profile in 
cognitive 
impairment
Amyloid 
pathology 
CSF 
profile 
P04217  A1BG_HUMAN  Alpha‐1B‐glycoprotein   118 0 ‐0.1518 0.2242 ‐0.1538         
P08697  A2AP_HUMAN  Alpha‐2‐antiplasmin   118 0 ‐0.0644 0.2241 ‐0.0566         
P02750  A2GL_HUMAN  Leucine‐rich alpha‐2‐glycoprotein   118 0 ‐0.1847 0.3656 ‐0.1302         
P01011  AACT_HUMAN  Alpha‐1‐antichymotrypsin   118 0 ‐0.1366 0.2297 ‐0.1264         
P62736#  ACTA_HUMAN#  Actin, aortic smooth muscle#   118 0 ‐0.8926 0.9408 ‐0.9313         
P60709#  ACTB_HUMAN#  Actin, cytoplasmic 1#   118 0 ‐0.7556 0.7864 ‐0.8273         
Q15848  ADIPO_HUMAN  Adiponectin   118 0 ‐0.1318 0.3529 ‐0.1083         
P43652  AFAM_HUMAN  Afamin   118 0 ‐0.1617 0.2902 ‐0.1819         
P35858  ALS_HUMAN 
Insulin‐like growth factor‐binding protein 
complex acid labile subunit   118 0 ‐0.1687 0.3041 ‐0.1663         
P02760  AMBP_HUMAN  Protein AMBP  118 0 ‐0.1523 0.2384 ‐0.1741         
P15144  AMPN_HUMAN  Aminopeptidase N   118 0 ‐0.09203 0.3349 ‐0.1177         
P03950  ANGI_HUMAN  Angiogenin   118 0 ‐0.1655 0.2811 ‐0.2067         
Q9Y5C1  ANGL3_HUMAN  Angiopoietin‐related protein 3   118 0 ‐0.08084 0.3301 ‐0.1187         
P01019  ANGT_HUMAN  Angiotensinogen   118 0 ‐0.1393 0.2643 ‐0.1367    ×    
P01008  ANT3_HUMAN  Antithrombin‐III   118 0 ‐0.1446 0.2074 ‐0.1739         
P02647  APOA1_HUMAN  Apolipoprotein A‐I   115 3 ‐0.4764 0.5642 ‐0.5486         
P02652  APOA2_HUMAN  Apolipoprotein A‐II   118 0 ‐0.398 0.9283 ‐0.5566         
P06727  APOA4_HUMAN  Apolipoprotein A‐IV   118 0 ‐0.1459 0.4276 ‐0.12         
P08519  APOA_HUMAN  Apolipoprotein  118 0 ‐0.9064 1.58 ‐1.172         
P04114  APOB_HUMAN  Apolipoprotein B‐100   118 0 ‐0.118 0.4624 ‐0.107         
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P02655  APOC2_HUMAN  Apolipoprotein C‐II   118 0 0.2051 0.7714 0.1695    ×    
P02656  APOC3_HUMAN  Apolipoprotein C‐III   118 0 0.1312 0.7042 0.1513         
P55056  APOC4_HUMAN  Apolipoprotein C‐IV   118 0 ‐0.05639 0.7286 ‐0.07604         
P05090  APOD_HUMAN  Apolipoprotein D   118 0 ‐0.1206 0.302 ‐0.112         
P02649  APOE_HUMAN  Apolipoprotein E   118 0 ‐0.04135 0.4088 ‐0.07157 ×       
P02749  APOH_HUMAN  Beta‐2‐glycoprotein 1   118 0 ‐0.1341 0.2946 ‐0.1676         
O14791  APOL1_HUMAN  Apolipoprotein L1   118 0 ‐0.1713 0.4537 ‐0.1916         
O95445  APOM_HUMAN  Apolipoprotein M   118 0 ‐0.1481 0.4373 ‐0.1748    ×    
P61160#  ARP2_HUMAN#  Actin‐related protein 2#   118 0 ‐0.9501 1.132 ‐0.8938         
P07307  ASGR2_HUMAN  Asialoglycoprotein receptor 2   118 0 ‐0.09116 0.3854 ‐0.08583         
O75882  ATRN_HUMAN  Attractin   118 0 ‐0.131 0.2614 ‐0.09691         
Q76LX8  ATS13_HUMAN 
A disintegrin and metalloproteinase with 
thrombospondin motifs 13   118 0 ‐0.0296 0.2598 ‐0.04933         
P61769  B2MG_HUMAN  Beta‐2‐microglobulin  118 0 ‐0.1901 0.3556 ‐0.2493         
Q15582  BGH3_HUMAN 
Transforming growth factor‐beta‐induced 
protein ig‐h3   118 0 ‐0.1258 0.2825 ‐0.1083         
P43251  BTD_HUMAN  Biotinidase   118 0 ‐0.1455 0.268 ‐0.1387         
A2RUR9  C144A_HUMAN 
Coiled‐coil domain‐containing protein 
144A  118 0 ‐0.2292 0.3097 ‐0.2742         
P02745  C1QA_HUMAN 
Complement C1q subcomponent subunit 
A  118 0 ‐0.1824 0.3281 ‐0.1716         
P02746  C1QB_HUMAN 
Complement C1q subcomponent subunit 
B  118 0 ‐0.1893 0.2599 ‐0.1929         
P02747  C1QC_HUMAN 
Complement C1q subcomponent subunit 
C  118 0 ‐0.1872 0.2585 ‐0.1964         
P00736  C1R_HUMAN  Complement C1r subcomponent   118 0 ‐0.1348 0.21 ‐0.1537         
Q9NZP8  C1RL_HUMAN 
Complement C1r subcomponent‐like 
protein   118 0 ‐0.1317 0.2979 ‐0.1222         
P09871  C1S_HUMAN  Complement C1s subcomponent   118 0 ‐0.1523 0.2257 ‐0.185         
P04003  C4BPA_HUMAN  C4b‐binding protein alpha chain   118 0 ‐0.1129 0.4514 ‐0.1349         
P20851  C4BPB_HUMAN  C4b‐binding protein beta chain  118 0 ‐0.06907 0.4524 ‐0.0954         
P55290  CAD13_HUMAN  Cadherin‐13   118 0 ‐0.1075 0.2354 ‐0.08777       × 
P33151  CADH5_HUMAN  Cadherin‐5   118 0 ‐0.08321 0.2746 ‐0.09096         
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P00915  CAH1_HUMAN  Carbonic anhydrase 1   118 0 ‐0.2405 0.5714 ‐0.2995         
P00918#  CAH2_HUMAN#  Carbonic anhydrase 2#   118 0 ‐0.3351 0.6546 ‐0.2994    ×    
P62158#  CALM_HUMAN#  Calmodulin#  118 0 ‐0.8015 1.216 ‐0.7403         
Q01518#  CAP1_HUMAN#  Adenylyl cyclase‐associated protein 1#   118 0 ‐0.8465 1.136 ‐0.8818         
P07339  CATD_HUMAN  Cathepsin D   118 0 ‐0.1755 0.3626 ‐0.1893         
P08185  CBG_HUMAN  Corticosteroid‐binding globulin   118 0 ‐0.1337 0.3455 ‐0.1603         
Q96IY4  CBPB2_HUMAN  Carboxypeptidase B2   118 0 ‐0.1423 0.2432 ‐0.1716         
P15169  CBPN_HUMAN  Carboxypeptidase N catalytic chain   118 0 ‐0.1682 0.2686 ‐0.1667         
Q9P1Z9  CC180_HUMAN 
Coiled‐coil domain‐containing protein 
180  114 4 ‐0.1388 0.4206 ‐0.0854    ×    
P08571  CD14_HUMAN  Monocyte differentiation antigen CD14   118 0 ‐0.1223 0.2607 ‐0.1282         
O43866  CD5L_HUMAN  CD5 antigen‐like   118 0 ‐0.3214 0.5788 ‐0.3355         
P00450  CERU_HUMAN  Ceruloplasmin   118 0 ‐0.2236 0.2735 ‐0.2107       × 
P00751  CFAB_HUMAN  Complement factor B   118 0 ‐0.1462 0.2818 ‐0.1384         
P00746  CFAD_HUMAN  Complement factor D   118 0 ‐0.1408 0.342 ‐0.1896         
P08603  CFAH_HUMAN  Complement factor H   118 0 ‐0.2002 0.2767 ‐0.1923         
P05156  CFAI_HUMAN  Complement factor I   118 0 ‐0.1472 0.2353 ‐0.1563         
P06276  CHLE_HUMAN  Cholinesterase   118 0 ‐0.1762 0.354 ‐0.1922         
O00299#  CLIC1_HUMAN#  Chloride intracellular channel protein 1#   118 0 ‐0.6921 1.058 ‐0.6656         
P10909  CLUS_HUMAN  Clusterin   118 0 ‐0.008554 0.2332 ‐0.009325         
Q96KN2  CNDP1_HUMAN  Beta‐Ala‐His dipeptidase   118 0 ‐0.1556 0.3449 ‐0.1666         
P06681  CO2_HUMAN  Complement C2   118 0 ‐0.1459 0.2201 ‐0.1523         
P01024  CO3_HUMAN  Complement C3   118 0 ‐0.2336 0.2465 ‐0.2393         
P0C0L4  CO4A_HUMAN  Complement C4‐A   118 0 ‐0.2496 0.6239 ‐0.1126         
P0C0L5  CO4B_HUMAN  Complement C4‐B   118 0 ‐0.1708 0.3555 ‐0.146       × 
P01031  CO5_HUMAN  Complement C5   118 0 ‐0.2247 0.2402 ‐0.2336         
P13671  CO6_HUMAN  Complement component C6  118 0 ‐0.1592 0.3223 ‐0.1377         
P10643  CO7_HUMAN  Complement component C7  118 0 ‐0.1559 0.2957 ‐0.1573 ×  ×  × 
P07357  CO8A_HUMAN  Complement component C8 alpha chain   118 0 ‐0.1534 0.2534 ‐0.1477         
P07358  CO8B_HUMAN  Complement component C8 beta chain   118 0 ‐0.1242 0.3075 ‐0.1211         
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P07360  CO8G_HUMAN 
Complement component C8 gamma 
chain  118 0 ‐0.1576 0.2355 ‐0.1754    ×    
P02748  CO9_HUMAN  Complement component C9  118 0 ‐0.1334 0.36 ‐0.1257         
P23528#  COF1_HUMAN#  Cofilin‐1#   118 0 ‐1.003 1.251 ‐0.9584         
P39060  COIA1_HUMAN  Collagen alpha‐1  118 0 ‐0.1492 0.2522 ‐0.1698         
Q9Y6Z7  COL10_HUMAN  Collectin‐10   118 0 ‐0.1091 0.2534 ‐0.08242         
Q9BWP8  COL11_HUMAN  Collectin‐11   118 0 ‐0.1459 0.2744 ‐0.1385         
P49747  COMP_HUMAN  Cartilage oligomeric matrix protein   118 0 ‐0.1243 0.3019 ‐0.09208         
P22792  CPN2_HUMAN  Carboxypeptidase N subunit 2   118 0 ‐0.1138 0.296 ‐0.09341         
Q9NQ79  CRAC1_HUMAN  Cartilage acidic protein 1   118 0 ‐0.0518 0.3076 ‐0.07464         
P54108  CRIS3_HUMAN  Cysteine‐rich secretory protein 3   118 0 ‐0.1477 0.3423 ‐0.1579         
P02741  CRP_HUMAN  C‐reactive protein  117 1 ‐0.8914 1.386 ‐1.074       × 
P21291#  CSRP1_HUMAN#  Cysteine and glycine‐rich protein 1#   114 4 ‐0.8139 1.57 ‐0.6383         
P02775#  CXCL7_HUMAN#  Platelet basic protein#   118 0 ‐0.8362 1.244 ‐0.7261         
P01034  CYTC_HUMAN  Cystatin‐C   118 0 ‐0.1499 0.2739 ‐0.1822         
Q16610  ECM1_HUMAN  Extracellular matrix protein 1   118 0 ‐0.2994 0.3581 ‐0.2995         
P06733#  ENOA_HUMAN#  Alpha‐enolase#   118 0 ‐0.4821 0.866 ‐0.4808         
P00488  F13A_HUMAN  Coagulation factor XIII A chain   118 0 ‐0.2153 0.2454 ‐0.214         
P05160  F13B_HUMAN  Coagulation factor XIII B chain   118 0 ‐0.1506 0.2414 ‐0.1527         
P00742  FA10_HUMAN  Coagulation factor X   118 0 ‐0.1199 0.2353 ‐0.1404         
P03951  FA11_HUMAN  Coagulation factor XI   118 0 ‐0.1883 0.2411 ‐0.186         
P00748  FA12_HUMAN  Coagulation factor XII   118 0 ‐0.1707 0.3614 ‐0.1395       × 
P12259  FA5_HUMAN  Coagulation factor V   118 0 ‐0.04017 0.2813 ‐0.0711         
P08709  FA7_HUMAN  Coagulation factor VII   114 4 ‐0.1547 0.3146 ‐0.1477         
P00740  FA9_HUMAN  Coagulation factor IX   118 0 ‐0.1338 0.2794 ‐0.1704         
P23142  FBLN1_HUMAN  Fibulin‐1   118 0 ‐0.135 0.2925 ‐0.1802         
Q12805  FBLN3_HUMAN 
EGF‐containing fibulin‐like extracellular 
matrix protein 1   118 0 ‐0.1428 0.27 ‐0.1454         
O75636  FCN3_HUMAN  Ficolin‐3   118 0 ‐0.2046 0.4357 ‐0.2011         
P02765  FETUA_HUMAN  Alpha‐2‐HS‐glycoprotein   118 0 ‐0.1171 0.2808 ‐0.1315         
Q9UGM5  FETUB_HUMAN  Fetuin‐B   118 0 ‐0.1394 0.3312 ‐0.1346         
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Q08830  FGL1_HUMAN  Fibrinogen‐like protein 1   114 4 ‐0.07815 0.42 ‐0.08464         
Q03591  FHR1_HUMAN  Complement factor H‐related protein 1   117 1 ‐0.4268 1.266 ‐0.05908       × 
P36980  FHR2_HUMAN  Complement factor H‐related protein 2   118 0 ‐0.2542 0.6162 ‐0.09342         
Q9BXR6  FHR5_HUMAN  Complement factor H‐related protein 5   118 0 ‐0.1465 0.267 ‐0.1228         
P02671  FIBA_HUMAN  Fibrinogen alpha chain  118 0 ‐0.5995 0.5304 ‐0.5592         
P02675  FIBB_HUMAN  Fibrinogen beta chain  118 0 ‐0.5894 0.5639 ‐0.5503    ×    
P02679  FIBG_HUMAN  Fibrinogen gamma chain  118 0 ‐0.6337 0.6019 ‐0.5949         
P02751  FINC_HUMAN  Fibronectin   118 0 ‐0.6088 0.7327 ‐0.566         
P04406#  G3P_HUMAN# 
Glyceraldehyde‐3‐phosphate 
dehydrogenase#   118 0 ‐0.3645 1.082 ‐0.3639         
P52566#  GDIR2_HUMAN#  Rho GDP‐dissociation inhibitor 2#   118 0 ‐0.6258 0.9865 ‐0.5765         
P06396  GELS_HUMAN  Gelsolin   118 0 ‐0.1283 0.261 ‐0.111         
Q9UJJ9  GNPTG_HUMAN 
N‐acetylglucosamine‐1‐
phosphotransferase subunit gamma   118 0 ‐0.09485 0.2113 ‐0.09463       × 
P22352  GPX3_HUMAN  Glutathione peroxidase 3   118 0 ‐0.1352 0.2293 ‐0.1305         
P09211  GSTP1_HUMAN  Glutathione S‐transferase P   114 4 ‐0.2787 0.3381 ‐0.2566         
Q14520  HABP2_HUMAN  Hyaluronan‐binding protein 2   118 0 ‐0.1101 0.2657 ‐0.1205         
P69905  HBA_HUMAN  Hemoglobin subunit alpha   114 4 ‐0.01683 0.2973 ‐0.0672    ×    
P02790  HEMO_HUMAN  Hemopexin   118 0 ‐0.1388 0.2269 ‐0.1405         
P05546  HEP2_HUMAN  Heparin cofactor 2   118 0 ‐0.0981 0.3049 ‐0.1071         
Q04756  HGFA_HUMAN  Hepatocyte growth factor activator   118 0 ‐0.1605 0.2921 ‐0.1503         
P26927  HGFL_HUMAN  Hepatocyte growth factor‐like protein   118 0 ‐0.1888 0.3912 ‐0.1253       × 
P04196  HRG_HUMAN  Histidine‐rich glycoprotein   118 0 ‐0.1975 0.5792 ‐0.1346         
O43365  HXA3_HUMAN  Homeobox protein Hox‐A3   118 0 ‐0.2561 0.6545 ‐0.17    ×    
Q9Y4L1  HYOU1_HUMAN  Hypoxia up‐regulated protein 1   118 0 ‐0.1268 0.2824 ‐0.1531         
P18065  IBP2_HUMAN 
Insulin‐like growth factor‐binding protein 
2   118 0 ‐0.168 0.4467 ‐0.1483 ×  ×  × 
P17936  IBP3_HUMAN 
Insulin‐like growth factor‐binding protein 
3   118 0 ‐0.1425 0.2407 ‐0.1517         
P22692  IBP4_HUMAN 
Insulin‐like growth factor‐binding protein 
4   118 0 ‐0.1503 0.251 ‐0.1787         
P24593  IBP5_HUMAN  Insulin‐like growth factor‐binding protein  118 0 ‐0.1176 0.262 ‐0.1119         
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P05155  IC1_HUMAN  Plasma protease C1 inhibitor   118 0 ‐0.1862 0.3529 ‐0.2082         
P13598  ICAM2_HUMAN  Intercellular adhesion molecule 2   118 0 ‐0.1373 0.3186 ‐0.1546    ×    
P01344  IGF2_HUMAN  Insulin‐like growth factor II   118 0 ‐0.1526 0.2928 ‐0.1431         
Q9NPH3  IL1AP_HUMAN  Interleukin‐1 receptor accessory protein   118 0 ‐0.1134 0.3386 ‐0.1489         
P55103  INHBC_HUMAN  Inhibin beta C chain   114 4 ‐0.02429 0.4146 ‐0.0005375         
P05154  IPSP_HUMAN  Plasma serine protease inhibitor   118 0 ‐0.09499 0.2863 ‐0.1064       × 
P19827  ITIH1_HUMAN 
Inter‐alpha‐trypsin inhibitor heavy chain 
H1   118 0 ‐0.1297 0.251 ‐0.1168         
P19823  ITIH2_HUMAN 
Inter‐alpha‐trypsin inhibitor heavy chain 
H2   118 0 ‐0.1461 0.2327 ‐0.1453         
Q06033  ITIH3_HUMAN 
Inter‐alpha‐trypsin inhibitor heavy chain 
H3   118 0 ‐0.1623 0.3844 ‐0.1926         
Q14624  ITIH4_HUMAN 
Inter‐alpha‐trypsin inhibitor heavy chain 
H4   118 0 ‐0.08849 0.2168 ‐0.1073         
Q2KHM9  K0753_HUMAN 
Uncharacterized protein KIAA0753, 
reviewed as protein moonraker 
(MOONR_HUMAN)   114 4 0.01047 0.5115 0.03482
   ×  × 
P04264  K2C1_HUMAN  Keratin, type II cytoskeletal 1   114 4 ‐0.1647 0.915 ‐0.2828         
P29622  KAIN_HUMAN  Kallistatin   118 0 ‐0.08967 0.2615 ‐0.1012         
Q96Q89  KI20B_HUMAN  Kinesin‐like protein KIF20B   118 0 ‐0.08375 0.3106 ‐0.07772         
P03952  KLKB1_HUMAN  Plasma kallikrein   118 0 ‐0.1745 0.3095 ‐0.2246         
P01042  KNG1_HUMAN  Kininogen‐1   118 0 ‐0.105 0.1947 ‐0.1293         
P14618#  KPYM_HUMAN#  Pyruvate kinase PKM#   118 0 ‐0.4708 0.7683 ‐0.5302       × 
P18428  LBP_HUMAN  Lipopolysaccharide‐binding protein   118 0 ‐0.08474 0.4077 ‐0.09975         
P07195  LDHB_HUMAN  L‐lactate dehydrogenase B chain   118 0 ‐0.2319 0.4322 ‐0.2658         
Q3ZCW2# LEGL_HUMAN#  Galectin‐related protein#   118 0 ‐0.3857 0.66 ‐0.4195         
Q08380  LG3BP_HUMAN  Galectin‐3‐binding protein   118 0 ‐0.08951 0.4951 ‐0.134         
P51884  LUM_HUMAN  Lumican   118 0 ‐0.1298 0.2862 ‐0.1048         
P14151  LYAM1_HUMAN  L‐selectin   118 0 ‐0.1712 0.3086 ‐0.1474         
P61626  LYSC_HUMAN  Lysozyme C   118 0 ‐0.1888 0.3783 ‐0.1764         
P33908  MA1A1_HUMAN  Mannosyl‐oligosaccharide 1,2‐alpha‐ 118 0 ‐0.1465 0.233 ‐0.1515         
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mannosidase IA 
P48740  MASP1_HUMAN  Mannan‐binding lectin serine protease 1   118 0 ‐0.1983 0.2722 ‐0.2186         
O00187  MASP2_HUMAN  Mannan‐binding lectin serine protease 2   118 0 ‐0.1379 0.272 ‐0.1364         
P11226  MBL2_HUMAN  Mannose‐binding protein C   118 0 ‐0.2075 0.4558 ‐0.216         
P20774  MIME_HUMAN  Mimecan   114 4 ‐0.1021 0.2606 ‐0.09706         
P08253  MMP2_HUMAN  72 kDa type IV collagenase   118 0 ‐0.09619 0.2326 ‐0.1179         
P02144  MYG_HUMAN  Myoglobin  114 4 ‐0.169 0.3857 ‐0.1869         
Q9Y2K3  MYH15_HUMAN  Myosin‐15   118 0 ‐0.04519 0.3517 ‐0.0659         
A7E2Y1  MYH7B_HUMAN  Myosin‐7B   118 0 ‐0.1177 0.3573 ‐0.1436         
O60524  NEMF_HUMAN  Nuclear export mediator factor NEMF   118 0 ‐0.1165 0.3251 ‐0.1679         
Q99784  NOE1_HUMAN  Noelin   114 4 ‐0.0944 0.2525 ‐0.09089 ×  ×    
O60287  NPA1P_HUMAN 
Nucleolar pre‐ribosomal‐associated 
protein 1   118 0 ‐0.1296 0.3319 ‐0.1588         
P15559  NQO1_HUMAN  NAD  118 0 ‐0.04222 0.3003 ‐0.04605         
Q7RTY7  OVCH1_HUMAN  Ovochymase‐1   114 4 ‐0.003395 0.2849 ‐0.03339    ×  × 
Q15113  PCOC1_HUMAN  Procollagen C‐endopeptidase enhancer 1   118 0 ‐0.1214 0.3306 ‐0.0828         
Q8NBP7  PCSK9_HUMAN 
Proprotein convertase subtilisin/kexin 
type 9   114 4 ‐0.1388 0.3151 ‐0.1166         
Q9UHG3  PCYOX_HUMAN  Prenylcysteine oxidase 1   118 0 ‐0.1434 0.3825 ‐0.19         
O00151#  PDLI1_HUMAN#  PDZ and LIM domain protein 1#   118 0 ‐0.7868 1.165 ‐0.854         
P36955  PEDF_HUMAN  Pigment epithelium‐derived factor   118 0 ‐0.1041 0.322 ‐0.1279         
P12955  PEPD_HUMAN  Xaa‐Pro dipeptidase   118 0 ‐0.2908 0.2427 ‐0.2779         
P98160  PGBM_HUMAN 
Basement membrane‐specific heparan 
sulfate proteoglycan core protein   114 4 ‐0.1862 0.3053 ‐0.1938         
P00558  PGK1_HUMAN  Phosphoglycerate kinase 1   118 0 ‐0.2238 0.5024 ‐0.1637         
Q96PD5  PGRP2_HUMAN  N‐acetylmuramoyl‐L‐alanine amidase   118 0 ‐0.1297 0.2547 ‐0.1187         
P80108  PHLD_HUMAN 
Phosphatidylinositol‐glycan‐specific 
phospholipase D   118 0 ‐0.07568 0.378 ‐0.07594         
Q6UXB8  PI16_HUMAN  Peptidase inhibitor 16   118 0 ‐0.1626 0.3636 ‐0.2044         
Q15149  PLEC_HUMAN  Plectin   118 0 ‐0.01254 0.3024 0.0067         
P08567#  PLEK_HUMAN#  Pleckstrin#   118 0 ‐0.8932 1.051 ‐0.838         
45 
 
P00747  PLMN_HUMAN  Plasminogen   118 0 ‐0.1637 0.2994 ‐0.1472         
P13796  PLSL_HUMAN  Plastin‐2   118 0 ‐0.1187 0.2693 ‐0.137         
P27169  PON1_HUMAN  Serum paraoxonase/arylesterase 1   118 0 ‐1.048 0.5318 ‐1.083         
Q15063  POSTN_HUMAN  Periostin   118 0 ‐0.1076 0.3567 ‐0.04761         
P62937#  PPIA_HUMAN#  Peptidyl‐prolyl cis‐trans isomerase A#   118 0 ‐0.9648 1.183 ‐0.9656         
P23284#  PPIB_HUMAN#  Peptidyl‐prolyl cis‐trans isomerase B#   118 0 ‐0.7734 0.7855 ‐0.7952         
P32119  PRDX2_HUMAN  Peroxiredoxin‐2   118 0 ‐0.3327 0.6442 ‐0.3301         
P30041#  PRDX6_HUMAN#  Peroxiredoxin‐6#   118 0 ‐0.4302 1.002 ‐0.4722         
Q92954  PRG4_HUMAN  Proteoglycan 4   118 0 ‐0.1398 0.3626 ‐0.1317         
P04070  PROC_HUMAN  Vitamin K‐dependent protein C   118 0 ‐0.1145 0.2622 ‐0.1298         
P07737#  PROF1_HUMAN#  Profilin‐1#   118 0 ‐0.7663 1.078 ‐0.784         
P27918  PROP_HUMAN  Properdin   118 0 ‐0.1697 0.2658 ‐0.1698         
P07225  PROS_HUMAN  Vitamin K‐dependent protein S  118 0 ‐0.06697 0.2691 ‐0.05886         
P22891  PROZ_HUMAN  Vitamin K‐dependent protein Z  118 0 ‐0.2003 0.5999 ‐0.1461         
P41222  PTGDS_HUMAN  Prostaglandin‐H2 D‐isomerase   118 0 ‐0.1551 0.289 ‐0.175         
P20742  PZP_HUMAN  Pregnancy zone protein   118 0 ‐0.3128 0.7697 ‐0.2925    ×    
O00391  QSOX1_HUMAN  Sulfhydryl oxidase 1   118 0 ‐0.1126 0.2062 ‐0.1112         
Q99969  RARR2_HUMAN 
Retinoic acid receptor responder protein 
2   118 0 ‐0.1616 0.3342 ‐0.1567         
P05451  REG1A_HUMAN  Lithostathine‐1‐alpha   118 0 ‐0.1451 0.4334 ‐0.139         
P02753  RET4_HUMAN  Retinol‐binding protein 4   118 0 ‐0.116 0.3363 ‐0.1002       × 
Q53QZ3  RHG15_HUMAN  Rho GTPase‐activating protein 15   118 0 ‐0.1917 0.2767 ‐0.1897         
P07998  RNAS1_HUMAN  Ribonuclease pancreatic   118 0 ‐0.1842 0.4214 ‐0.216         
P34096  RNAS4_HUMAN  Ribonuclease 4   118 0 ‐0.1609 0.2556 ‐0.184         
P62979#  RS27A_HUMAN#  Ubiquitin‐40S ribosomal protein S27a#   118 0 ‐0.6083 0.6899 ‐0.6866         
P06703#  S10A6_HUMAN#  Protein S100‐A6#   118 0 ‐0.3874 0.7144 ‐0.4101         
P05109  S10A8_HUMAN  Protein S100‐A8   118 0 ‐0.4547 0.7919 ‐0.5549         
P06702  S10A9_HUMAN  Protein S100‐A9   118 0 ‐0.4377 0.725 ‐0.559         
P0DJI8  SAA1_HUMAN  Serum amyloid A‐1 protein   118 0 ‐0.1987 0.8143 ‐0.2453         
P02743  SAMP_HUMAN  Serum amyloid P‐component   118 0 ‐0.3371 0.4685 ‐0.3659    ×    
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P49908  SEPP1_HUMAN  Selenoprotein P   118 0 ‐0.06431 0.2893 ‐0.098    ×    
Q7Z333  SETX_HUMAN  Probable helicase senataxin   114 4 ‐0.113 0.2729 ‐0.1068         
O75368#  SH3L1_HUMAN# 
SH3 domain‐binding glutamic acid‐rich‐
like protein#  118 0 ‐0.4995 0.8764 ‐0.5311         
Q9H299#  SH3L3_HUMAN# 
SH3 domain‐binding glutamic acid‐rich‐
like protein 3#   118 0 ‐0.7534 1.124 ‐0.6808         
P04278  SHBG_HUMAN  Sex hormone‐binding globulin   118 0 ‐0.1564 0.4752 ‐0.1705       × 
P03973  SLPI_HUMAN  Antileukoproteinase   118 0 ‐0.107 0.3078 ‐0.1069         
P00441#  SODC_HUMAN#  Superoxide dismutase [Cu‐Zn] #   118 0 ‐0.4151 0.5544 ‐0.4349         
Q13103  SPP24_HUMAN  Secreted phosphoprotein 24   118 0 0.1501 0.5418 0.159         
P11277  SPTB1_HUMAN  Spectrin beta chain, erythrocytic   114 4 ‐0.05267 0.4516 0.001725         
Q01082  SPTB2_HUMAN  Spectrin beta chain, non‐erythrocytic 1   118 0 ‐0.1329 0.4151 ‐0.09646         
Q96C24  SYTL4_HUMAN  Synaptotagmin‐like protein 4   118 0 ‐0.06331 0.2124 ‐0.04308         
P37840#  SYUA_HUMAN#  Alpha‐synuclein#   118 0 ‐0.3043 0.8879 ‐0.402         
P37802#  TAGL2_HUMAN#  Transgelin‐2#   118 0 ‐0.8592 1.152 ‐0.7877         
Q9BYX2  TBD2A_HUMAN  TBC1 domain family member 2A   118 0 ‐0.1357 0.3085 ‐0.1599         
P22105  TENX_HUMAN  Tenascin‐X   114 4 ‐0.1479 0.2728 ‐0.173         
P05452  TETN_HUMAN  Tetranectin   118 0 ‐0.1094 0.2036 ‐0.1         
P05543  THBG_HUMAN  Thyroxine‐binding globulin   118 0 ‐0.1437 0.2296 ‐0.1585         
P10599#  THIO_HUMAN#  Thioredoxin#   118 0 ‐0.3641 0.7664 ‐0.4164         
P00734  THRB_HUMAN  Prothrombin   118 0 ‐0.1221 0.2311 ‐0.1406         
P01033  TIMP1_HUMAN  Metalloproteinase inhibitor 1   118 0 ‐0.1756 0.3414 ‐0.1835         
P16035  TIMP2_HUMAN  Metalloproteinase inhibitor 2   118 0 ‐0.1121 0.2401 ‐0.1435         
Q8WZ42  TITIN_HUMAN  Titin   118 0 ‐0.1687 0.2159 ‐0.1726         
Q9Y490#  TLN1_HUMAN#  Talin‐1#  118 0 ‐0.4711 0.7136 ‐0.4417         
P67936#  TPM4_HUMAN#  Tropomyosin alpha‐4 chain#   118 0 ‐1.061 1.209 ‐1.086         
P07996#  TSP1_HUMAN#  Thrombospondin‐1#  118 0 ‐0.4236 0.7338 ‐0.4406    ×    
P02766  TTHY_HUMAN  Transthyretin   118 0 ‐0.004292 0.6448 0.009837         
P62328#  TYB4_HUMAN#  Thymosin beta‐4#   118 0 ‐0.968 1.572 ‐0.6693         
Q86UX7  URP2_HUMAN#  Fermitin family homolog 3#   118 0 ‐0.3894 0.6739 ‐0.3669         
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Q6EMK4  VASN_HUMAN  Vasorin   118 0 ‐0.1229 0.2018 ‐0.1061         
P18206#  VINC_HUMAN#  Vinculin#   118 0 ‐0.5185 0.6759 ‐0.5553         
P02774  VTDB_HUMAN  Vitamin D‐binding protein   118 0 ‐0.1591 0.2739 ‐0.152         
P04004  VTNC_HUMAN  Vitronectin   118 0 ‐0.1224 0.2932 ‐0.142         
P04275  VWF_HUMAN  von Willebrand factor   118 0 ‐0.2175 0.4241 ‐0.2522         
P25311  ZA2G_HUMAN  Zinc‐alpha‐2‐glycoprotein   118 0 ‐0.1529 0.3407 ‐0.1625         
Q9UK55  ZPI_HUMAN  Protein Z‐dependent protease inhibitor   118 0 ‐0.1289 0.3055 ‐0.1162         
Q15942#  ZYX_HUMAN#  Zyxin#   118 0 ‐0.5832 0.9187 ‐0.5192         
P63104#  1433Z_HUMAN#  14‐3‐3 protein zeta/delta#   118 0 ‐0.805 0.9321 ‐0.7811         
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SUPPLEMENTARY FIGURES 
 
 
 
Figure S1. Supervised determination of CSF P-tau181/Aβ1-42 (A) and Aβ1-42 (B) cutoffs from 
the 48 healthy volunteers with normal cognition and 72 memory clinic patients with MCI or mild 
dementia of AD type. The vertical black lines indicate the fitted value that maximized the 
Youden index (= sensitivity + specificity - 1) in the ROC analysis predicting CDR categories 
(CDR = 0 versus CDR > 0). It corresponds to a cutoff of 0.0779 and 724 pg/mL for CSF P-
tau181/Aβ1-42 ratio and CSF Aβ1-42 concentration, respectively. 
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Figure S2. Heatmap of plasma proteome profiles after hierarchical clustering. Features = 
proteins; Observations = samples.    
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Figure S3. Plot displaying the sensitivities, specificities, Youden indexes, and accuracies of all 
possible cutoffs of the models including plasma proteins for classification of non-AD versus AD 
CSF biomarker profiles (i.e., P-tau181/Aβ1-42 ≤ 0.0779 and P-tau181/Aβ1-42 > 0.0779 
respectively) in all subjects (A) and in subjects with cognitive impairment (B). 
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Figure S4. Box-plots of plasma proteins according to CSF P-tau181/Aβ1-42 ratio, i.e., “low” 
when P-tau181/Aβ1-42 ≤ 0.0779 and “high” when P-tau181/Aβ1-42 > 0.0779 for negative and 
positive CSF profiles of AD pathology, respectively. Relative protein fold change ratios were 
used. Level of significant is indicated as p-value after Bonferroni correction.  
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Figure S5. Box-plots of plasma proteins in cognitive impairment (i.e., subset of individuals with 
CDR > 0) according to CSF P-tau181/Aβ1-42 ratio, i.e., “low” when P-tau181/Aβ1-42 ≤ 0.0779 
and “high” when P-tau181/Aβ1-42 > 0.0779 for negative and positive CSF profiles of AD 
pathology, respectively. Relative protein fold change ratios were used. Level of significant is 
indicated as p-value after Bonferroni correction. 
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Figure S6. Plot displaying the sensitivities, specificities, Youden indexes, and accuracies of all 
possible cutoffs of the model including plasma proteins predictive of CSF Aβ1-42 levels. 
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SUPPLEMENTARY METHODS 
Materials. Iodoacetamide (IAA), tris(2-carboxyethyl) phosphine hydrochloride (TCEP), 
triethylammonium hydrogen carbonate buffer 1 M pH = 8.5, sodium dodecyl sulfate, and β-
lactoglobulin (LACB) from bovine milk were purchased from Sigma (St. Louis, MO, USA). 
Formic acid (FA, 99%) and CH3CN were from BDH (VWR International Ltd., Poole, UK). 
Hydroxylamine solution 50 wt % in H2O (99.999%) was acquired from Aldrich (Milwaukee, WI, 
USA). H2O (18.2 MΩ·cm at 25 °C) was obtained from a Milli-Q apparatus (Millipore, Billerica, 
MA, USA). Trifluoroacetic acid Uvasol® was sourced from Merck Millipore (Billerica, MA, 
USA). The 6-plex TMTs [24] were purchased from Thermo Scientific (Rockford, IL, USA). 
Sequencing grade modified Lys-C/trypsin was procured from Promega (Madison, WI, USA).  
For immuno-affinity depletion of 14 abundant human proteins, multiple affinity removal system 
(MARS) columns, Buffer A, and Buffer B were obtained from Agilent Technologies 
(Wilmington, DE, USA). Oasis HLB cartridges (1cc, 30 mg) were acquired from Waters 
(Milford, MA, USA) and Strata-X 33u Polymeric reversed-phase (RP) and Strata-X-C 33u 
Polymeric strong cation-exchange (SCX) solid-phase extraction (SPE) cartridges (30 mg/1 mL) 
from Phenomenex (Torrance, CA, USA). 
Sample preparation for proteomic analysis. From 25 µL of each plasma sample (diluted in 75 
µL of Buffer A containing 0.0134 mg·mL−1 LACB and filtered with 0.22 µm filter plate from 
Millipore), 14 abundant plasma proteins were removed, following the manufacturer instructions, 
with MARS columns and high performance liquid chromatography (HPLC) systems (Thermo 
Scientific, San Jose, CA, USA) equipped with an HTC-PAL (CTC Analytics AG, Zwingen, 
Switzerland) fraction collectors. After immuno-depletion, samples were snap-freezed and stored 
at -80 °C. Buffer exchange was performed with RP cartridges mounted on a 96-hole holder and a 
vacuum manifold, as previously described [10]. Samples were subsequently evaporated with a 
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vacuum centrifuge (Thermo Scientific) and stored at -80 °C. Reduction with TCEP, alkylation 
with IAA, digestion with Lys-C/trypsin, TMT 6-plex labeling, sample pooling, and SPE 
purification (Oasis HLB and SCX) were performed on a 4-channels Microlab Star liquid handler 
(Hamilton, Bonaduz, Switzerland) according to a previously reported protocol [10]. The pooled 
6-plex TMT-labeled samples were then evaporated to dryness before storage at -80 °C. 
Reversed-phase liquid chromatography tandem mass spectrometry. The samples were dissolved 
in 500 µL H2O/CH3CN/FA 96.9/3/0.1 for RP liquid chromatography tandem mass spectrometry 
(LC MS/MS). RP-LC MS/MS was performed with hybrid linear ion trap-Orbitrap (LTQ-OT) 
Elite and an Ultimate 3000 RSLC nano system (Thermo Scientific) as recently described [10]. 
Proteolytic peptides (injection of 5 µL of sample) were trapped on an Acclaim PepMap 75 µm × 
2 cm (C18, 3 µm, 100 Å) pre-column and separated on an Acclaim PepMap RSLC 75 µm × 50 
cm (C18, 2 µm, 100 Å) column (Thermo Scientific) coupled to a stainless steel nanobore emitter 
(40 mm, OD 1/32”) mounted on a Nanospray Flex Ion Source (Thermo Scientific). The analytical 
separation was run for 150 min using a gradient that reached 30% of CH3CN after 140 min and 
80% of CH3CN after 150 min at a flow rate of 220 nL·min−1.  For MS survey scans, the OT 
resolution was 120000 (ion population of 1 × 106) with an m/z window from 300 to 1500. For 
MS/MS with higher-energy collisional dissociation (HCD) at 35% of the normalized collision 
energy, ion population was set to 1 × 105 (isolation width of 2), with a resolution of 15000, first 
mass at m/z = 100, and a maximum injection time of 250 ms in the OT. A maximum of 10 
precursor ions (most intense) were selected for MS/MS. Dynamic exclusion was set for 60 
seconds within a ± 5 ppm window. A lock mass of m/z = 445.1200 was used. Each sample was 
analyzed in duplicate. 
Data analysis. Proteome Discoverer (version 1.4, Thermo Scientific) was used as data analysis 
interface. Identification was performed against the human UniProtKB/Swiss-Prot database 
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(08/12/2014 release) including the LACB sequence (20194 sequences in total). Mascot (version 
2.4.2, Matrix Science, London, UK) was used. Variable amino acid modifications were oxidized 
methionine, deamidated asparagine/glutamine, and 6-plex TMT-labeled peptide amino terminus 
(+ 229.163 Da). 6-plex TMT-labeled lysine (+ 229.163 Da) was set as fixed modifications as well 
as carbamidomethylation of cysteine. Trypsin was selected as the proteolytic enzyme, with a 
maximum of two potential missed cleavages. Peptide and fragment ion tolerance were set to, 
respectively, 10 ppm and 0.02 Da. All Mascot result files were loaded into Scaffold Q+S 4.4.1.1 
(Proteome Software, Portland, OR, USA) to be further searched with X! Tandem (version 
CYCLONE (2010.12.01.1)). Both peptide and protein FDRs were fixed at 1% maximum, with a 
2 unique peptide criterion to report protein identification. Quantitative values were exported from 
Scaffold Q+S as log2 of the protein ratio fold changes with respect to their measurements in the 
biological reference, i.e., mean log2 values after isotopic purity correction but without 
normalization applied between samples and experiments. The biological reference was a pool of 
all individual plasma samples labelled with 6-plex TMT reporter-ions at m/z = 126 and 131, 
allowing ratio fold change calculation with respect to both channels. Because of the concordance 
between both calculation results, the average of the values was done as well as the average of 
both replicate measurements. 
CSF Aβ1-42, tau, and P-tau181. CSF Aβ1-42, total-tau (tau), and tau phosphorylated at 
threonine 181 (P-tau181) concentrations were measured using commercially available ELISA 
kits (Fujirebio, Ghent, Belgium). 
APOE genotyping. DNA was extracted from whole blood using the QIAsymphony DSP DNA 
Kit (Qiagen, Hombrechtikon, Switzerland). The single nucleotide variant rs429358 and rs7412 
were genotyped using the Taqman assays C___3084793_20 and C____904973_10 respectively 
(Thermo Fischer Scientific, Waltham, MA, USA). 
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